Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Q: Paragraph: "Bounciest Democrat on November's statewide ballot? It might be Hank Gilbert, making his second hard charge for state agriculture commissioner versus Todd Staples, the Republican who topped him four years ago. Gilbert, ever prowling for issues, recently trumpeted that the Texas Department of Agriculture is looking at buying thousands of stress balls -- squeezable toys. He said in a Sept. 24 press release: ""Make no mistake, Texans love their balls: footballs, baseballs, basketballs, and soccer balls. But 300,000 stress balls? It seems a little extreme, but that's the quantity of grape, barbell, and book-shaped polyurethane stress balls the Texas Department of Agriculture could be spending taxpayer dollars on...""  Really? To our inquiry, Gilbert's campaign provided Web links to the agriculture agency's June request for bids as well as a September post on a state website indicating that a $99,000 contract to provide promotional materials was awarded to a Massachusetts company, Oceans Promotions. We downloaded the June 29 bid-request package from a site for state requisitions overseen by the state comptroller's office. The package shows the department was seeking bids to provide up to 300,000 stress ""relievers,"" which we're guessing are not balls because they're not round. Precisely, the package says, the agency sought bids to make ""promotional items with logo imprints to follow through on (the) TDA Food and Nutrition Texans Bring It Campaign,"" with the items to include grape-shaped stress relievers with ""Texans Bring It"" written on them or ""Eating Right,"" which would be made of polyurethane and be two inches high by three inches wide. The package says a second set of stress relievers, each one called ""Dumbbell,"" would be imprinted ""Texans Bring It"" and ""Exercise"" and be five inches high by 1.8 inches in diameter. A third stress reliever would be imprinted ""Book"" and ""Texans Bring It,"" according to the bid package, while other promotional items would include pencils, buttons and bumperstickers. The package says the bids were sought for various quantities, starting from 2,500 and topping out at 100,000 each. It electronically links to a Branders.com site showing what the agency wanted the stress relievers to look like (our interpretation: bunches of purple grapes). Is all this a real deal? To our inquiry, Bryan Black, Staples' spokesman, replied via e-mail: ""An invitation for bid was issued for these federally funded educational items to reduce the $5.8 billion avoidable health care expenditures, paid by taxpayers, associated with overweight and obesity health problems."" We followed up with Black, asking if it's accurate to conclude that up to 300,000 of the stress relievers are being purchased. We also wondered why the purchase was being made. Black said he'd limit his comment to his e-mailed statement. Surely the agency would pipe up if Gilbert got its purchase plans wrong." Claim: Hank Gilbert Says the Texas Department of Agriculture seeks to purchase up to 300,000 promotional stress balls.

A: Hank Gilbert says Texas Department of Agriculture could be buying up to 300,000 stress balls
****
Q: Paragraph: No company wants to be the next LM Wind Power. “All it takes is to see something like that happen in a neighboring business or a business similar to yours and everyone gets a lot more fastidious with control measures,” said Dr. Paul Carson, a public health and infectious disease specialist at North Dakota State University, referring to the spread at the Grand Forks plant. Officials with two of the state’s largest plants, window and door maker Marvin and agriculture and construction components producer John Deere Electronic Solutions, say there are new rules of the road. And they’re doing more than the standard protocol of proper hygiene, high-tech protective gear, social distancing and stickers that say, “IF YOU CAN READ THIS YOU ARE TOO CLOSE.” Hallways, entrances, and exits are strictly one-way. Other changes have included temperature checks, unique equipment like “no touch” door openers, liberal leave policies and pay provisions, and an added emphasis on communication between management and workers. ’“The stakes are too high right now,” said Paul Marvin, CEO of Marvin, a century-old Warroad, Minnesota-based company with 6,000 employees in eight states, including 1,300 in the Fargo area. “We want to make people feel comfortable and build trust. It costs you a little money in the short term but it pays dividends in the long run.” The John Deere Electronic Solutions plant in Fargo employs about 750 people. A company spokeswoman said “one of the most impactful steps” they’ve taken is to assure employees that they will be paid if they have symptoms of the virus, don’t feel well or believe they could have been exposed. Marvin employees receive paid leave if they are sick and unpaid leave with health benefits if they just don’t feel comfortable going to work. Paul Marvin said employees don’t have to “prove how sick they are” with notes from their doctors. And their jobs will be waiting for them when they return. North Dakota Gov. Doug Burgum has held up a Canada-based potato processing business as the gold standard for protecting employees from the coronavirus, stating that Cavendish Farms plants in North Dakota and elsewhere have not recorded a single COVID-19 case among thousands of workers. The company employs 250 people at its Jamestown plant. “It has been a family owned-business for decades, taking care of their people,” Burgum said. “They have a culture of safety that has been long established. It’s easy for them to take it up another level.” Cavendish Farms spokeswoman Mary Keith said the numerous safeguards include infrared cameras to monitor the temperatures of people entering buildings and hundreds of signs in multiple languages placed throughout the plants to make employees aware of social distancing and other guidelines. The company purchased 2,700 plexiglass face shields for all of its operations and has added floor-to-ceiling barriers made of plexiglass or wood, she said. “We feel that what we did very well is we reacted early and we reacted fast to the risk and escalated our measures,” Keith said, adding that workers awaiting testing or treatment for COVID-19 receive 10 paid days with health benefits. Meanwhile, the number of infected workers at LM Wind Power stands at about 150 at the Grand Forks plant that employs about 900 people. State and local health officials are undertaking a vigorous contact tracing effort, recruiting dozens of people to help find other COVID-19 cases related to the plant. Some LM employees have complained publicly about what they believed to be a lack of safety precautions, which the company has denied. Officials with the Department of Labor and Human Rights have not received any complaints from LM employees, according to Burgum spokesman Mike Nowatzki. Scott Weislow, Marvin’s director of enterprise risk management, said Marvin had a pandemic blueprint in its library after dealing with the Avian flu and that gave them a head start, he said. “I think we’re going to see an evolution in business; not just us but everybody,” Weislow said. “Working from home will be more acceptable. Some of these social distancing measures are probably going to stick around and you’re going to see other measures like voice activated lights and voice activated door openers.” Carson said when it comes to the coronavirus, even the most stringent measures may not be enough to dodge “the luck of the draw.” It only takes one infected person who’s not showing symptoms to start the spread, he said. Claim: Grand Forks outbreak has other North Dakota plants on alert.

A: A widespread outbreak of the coronavirus that has shuttered a wind turbine plant in northeastern North Dakota and initiated a massive contact tracing effort has led many of the state’s largest manufacturers to review and relay their safety measures.
****
Q: Paragraph: "Cost data for flibanserin is not provided. Some projection of cost should be available for any drug this far along in Phase III trials – and for which the company has already begun marketing campaigns. If not from the company, then from stock analysts. The story properly quantifies the reported benefits in absolute terms which allows the reader to see that they are small. (Results are described in Quality of Evidence comments.) In an interview a study researcher conceded that the absolute number of women reporting benefit was not large. The story provided statistics on common side effects including daytime sleepiness, dizziness, fatigue, anxiety, dry mouth, nausea and insomnia. These side effects resulted in 15% of those taking flibanserin vs 7% taking placebo withdrawing from the study. The story does a good job of presenting and evaluating the available evidence. Results are presented in absolute terms, for example that just under one third of women taking flibanserin reported improvement in sexual distress/desire compared to approximately one fifth of women taking placebo. In contrast, these results were presented in relative terms by the manufacturer. Except for the headline, "" ‘Female Viagra’ May Treat Low Sexual Desire"", this story avoids disease mongering and notes that ""hypoactive sexual desire disorder"" in women is a controversial diagnosis. The text clarifies that while the popular press is dubbing flibanserin as the ""female Viagra"", it is not similar to Viagra or other drugs to treat erectile dysfunction. Conflicts of interest are disclosed. The story noted that the study researcher interviewed is a paid consultant for the drug manufacturer. An alternative point of view is provided by two independent experts, a psychologist and a sex-therapist. The independent sources comment on the role that personal relationships play in sexual desire and experience which was not addressed or acknowledged by the researchers. The story indicates that an alternative drug called the Intrinsa testosterone patch is available in Europe, but not in the U.S. The story also notes a difference between these dugs; Intrinsa is a hormonal treatment compared to flibanserin which is a non-hormonal. The story indirectly informs that reader that flibanserin is not available by noting that it is in phase III clinical trials and that the manufacturer is seeking FDA approval (despite early direct to consumer marketing campaigns). The story makes it fairly clear that this is a new treatment – also for a new and controversial diagnosis. The story was apparently based on research presented in abstract form at the annual clinical meeting of the American College of Gynecologists and Obstetricians, although this information has not been published in independently, peer-referred scientific journals. There is no direct evidence that it relied largely on a news release. In fact, the use of interviews with independent experts makes it clear that independent reporting took place." Claim: ‘Female Viagra’ May Treat Low Sexual Desire

A:
"This story reports on a investigational drug, flibanserin, that is being developed to treat what is a controversial diagnosis called ""hypoactive sexual desire"" in women. The popular press has dubbed this drug ""Female Viagra"" despite that fact that it has few similarities to drugs that treat erectile dysfunction. Preliminary research examining the drug’s efficacy in treating sexual distress and/or low sexual desire were presented at the May 2010 annual clinical meeting of the American College of Obstetricians and Gynecologists (ACOG). To place the story in context, previous reports from the manufacturer claimed that flibanserin resulted in ""clinically significant"" improvement in the number of sexually satisfying events reported by women taking the drug vs. those taking placebo, an absolute difference of 0.7 events per month. The story was detailed and did a good job of presenting information in absolute terms so that the reader could clearly see that reported benefits were small and of unknown clinical significance. Good reminders that this is a controversial diagnosis and that ""some experts see it as the medicalization of what is for many women a relationship issue."""
****